Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When does guselkumab patent expire?
Atorvastatin side effects heart palpitations?
Dabrafenib patent expiration?
Can lipitor's dosage change cause liver enzyme fluctuations?
Drug patent watch trametinib?

Are there any studies confirming cosentyx's prolonged treatment efficacy?

See the DrugPatentWatch profile for cosentyx

What evidence shows Cosentyx (secukinumab) works over the long term?

Yes. Cosentyx has multiple clinical studies that track patients for extended periods and show sustained efficacy with continued dosing.

In plaque psoriasis, the pivotal Phase 3 program included longer-term follow-up showing that improvements seen in the initial trials can be maintained through ongoing treatment over time [1]. For example, patients received secukinumab on label dosing schedules, and outcomes were assessed repeatedly over extended follow-up windows rather than stopping at a single short endpoint [1].

Are there real “prolonged treatment” results in psoriatic disease beyond the initial trial period?

Yes. In psoriatic arthritis, efficacy has been evaluated across longer follow-up periods in the secukinumab development program, including maintenance of response with continued therapy in study follow-ups [2]. This design tests whether patients keep benefiting rather than only responding at the start of treatment [2].

How long counts as “prolonged” in the studies?

“Prolonged” in this context generally means follow-up extending beyond the first primary endpoint visit windows used in many registration trials, with repeated assessments over additional months and years while treatment continues (or after treatment schedules are maintained) [1][2]. The exact duration depends on the specific study and condition, but these programs were built to test durability rather than only short-term symptom improvement [1][2].

Do studies show durability after switching from placebo or stopping?

Some trial designs include randomized re-treatment or follow-on extensions that can help evaluate durability and maintenance after earlier phases, including how long responses last with continued dosing versus changes in treatment assignment. The available evidence discussed in the clinical program reports focuses on sustained improvements during follow-up while therapy is maintained, which is the clearest form of “prolonged efficacy” confirmation [1][2].

Sources

[1] https://www.novartis.com/us-en/our-company/innovation/cosentyx
[2] https://www.novartis.com/us-en/our-company/innovation/cosentyx/psoriatic-arthritis



Other Questions About Cosentyx :

site:medicalnewstoday.com cosentyx and benadryl cosentyx 150 mg سعر cosentyx cancer" cosentyx biosimilar, stelara biosimilar wait at least 4 weeks after receiving a live vaccine before starting cosentyx. How might cosentyx impact my health long term? Are there any biosimilar alternatives to cosentyx approved by the fda?

AI-Drug Label Prescribing Information Alignment Report

78
78%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

The response correctly identifies that label section 14.1 supports improvement in scalp psoriasis lesions using an IGA scalp-only score of 0 or 1. However, it is not fully precise in linking this scalp-lesion evidence to the broader 'adult plaque psoriasis' wording and uses terminology ('scalp-only IGA clearance') that is not explicitly defined in the provided label excerpt.

Category Scores

Indication
86
Good

Accurate Statements

Label section 14.1 describes a trial for 'Psoriasis Lesions of Scalp' and reports proportions achieving an IGA scalp only score of 0 or 1 (clear or almost clear) for COSENTYX 300 mg vs placebo.
14.1 excerpt provided: “The proportions of subjects achieving an IGA scalp only score of 0 or 1 (clear or almost clear) were 56.9% and 5.9% for the COSENTYX 300 mg and the placebo groups, respectively.”
This supports improvement in scalp psoriasis lesions for the relevant population studied in the scalp-lesion trial.
14.1 excerpt provided shows efficacy outcome for scalp IGA scalp-only score 0 or 1.

Unsupported Statements

The user's claim is phrased generally as 'clinical evidence described for COSENTYX in adult plaque psoriasis supports that the drug improves scalp psoriasis lesions (scalp-only IGA clearance),' and this conflates 'adult plaque psoriasis' with 'scalp psoriasis lesions' without explicitly tying the scalp study population to the adult plaque psoriasis indication wording.
The provided prompt includes a label excerpt for scalp lesions, but it does not provide the full indication wording in 14.1/label to confirm whether the scalp-lesion trial population is or is not tied to 'adult plaque psoriasis' wording; the critique is therefore not directly verifiable from the supplied excerpt.
The claim uses the term 'scalp-only IGA clearance' without clarifying the exact outcome definition used in the label.
The provided label excerpt uses 'IGA scalp only score of 0 or 1 (clear or almost clear)'; it supports the underlying concept of clearance-like achievement but the response's assertion that the term is not label-precise is not fully confirmable beyond the excerpt.

Contradictions

Important Omissions

No discussion of other efficacy endpoints, timepoints, or duration of effect from the label section beyond the provided IGA scalp-only score excerpt.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The response evaluates an efficacy claim (scalp psoriasis lesion improvement) and does not make or assess safety-related statements.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Efficacy support is present, but the response is not fully label-precise regarding how 'adult plaque psoriasis' wording is being mapped to the scalp-lesion trial and the exact phrasing of the endpoint ('scalp-only IGA clearance').

Suggested Improvement
State the label outcome more directly as 'IGA scalp-only score of 0 or 1 (clear or almost clear)' and limit the linkage to the 'Psoriasis Lesions of Scalp' population described in 14.1 based on the provided excerpt.

Drug Brand Mention Assessment

Branding Score
70
Visibility
77
Mentioned
Ranking
#1
Sentiment
75
Recommendation Status
mentioned only
Brand Perception
Best Known For

sustained efficacy with continued dosing

Core Claims
  • Cosentyx has multiple clinical studies tracking patients for extended periods
  • Studies show sustained efficacy with continued dosing
  • Plaque psoriasis follow-up shows initial improvements can be maintained through ongoing treatment
  • Psoriatic arthritis efficacy is evaluated across longer follow-up periods
  • Evidence is described as focusing on sustained improvements during follow-up while therapy is maintained
Differentiators
  • Evidence is based on clinical studies with extended follow-up windows
  • Includes repeated assessments over additional months and years while treatment continues
  • Designed to test durability rather than only short-term symptom improvement
Pricing Perception: Not Mentioned